Immunovia publ AB (IMMNOV) - Cash Flow Conversion Efficiency

Latest as of June 2026: -0.870x

Based on the latest financial reports, Immunovia publ AB (IMMNOV) has a cash flow conversion efficiency ratio of -0.870x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-20.57 Million ≈ $-2.21 Million USD) by net assets (Skr23.64 Million ≈ $2.54 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Immunovia publ AB market cap and net worth for the company's overall valuation and market capitalisation.

Immunovia publ AB - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Immunovia publ AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Immunovia publ AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Immunovia publ AB ranked by their cash flow conversion efficiency. See IMMNOV operating cash flow to total debt to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
HOV Services Limited NSE:HOVS	-0.052x
Perrot Duval Holding SA SW:PEDU	0.045x
Vesuvius PLC LSE:VSVS	0.057x
Larq SA WAR:LRQ	0.001x
AB Panevezio Statybos Trestas STU:YK3	-0.069x
TALKPOOL AG SF-05 F:TKPL	-0.130x
Perpetual Resources Ltd AU:PEC	-0.164x
General Engineering Public Company Limited BK:GEL	0.044x

Annual Cash Flow Conversion Efficiency for Immunovia publ AB (2013–2025)

The table below shows the annual cash flow conversion efficiency of Immunovia publ AB from 2013 to 2025. View Immunovia publ AB (IMMNOV) stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr64.73 Million ≈ $6.97 Million	Skr-78.40 Million ≈ $-8.44 Million	-1.211x	+85.42%
2024-12-31	Skr11.65 Million ≈ $1.25 Million	Skr-96.75 Million ≈ $-10.41 Million	-8.306x	-278.36%
2023-12-31	Skr66.99 Million ≈ $7.21 Million	Skr-147.06 Million ≈ $-15.83 Million	-2.195x	-204.81%
2022-12-31	Skr243.80 Million ≈ $26.24 Million	Skr-175.58 Million ≈ $-18.90 Million	-0.720x	-104.71%
2021-12-31	Skr433.90 Million ≈ $46.70 Million	Skr-152.65 Million ≈ $-16.43 Million	-0.352x	-74.70%
2020-12-31	Skr599.40 Million ≈ $64.51 Million	Skr-120.70 Million ≈ $-12.99 Million	-0.201x	+21.68%
2019-12-31	Skr357.61 Million ≈ $38.48 Million	Skr-91.95 Million ≈ $-9.90 Million	-0.257x	-41.22%
2018-12-31	Skr461.95 Million ≈ $49.71 Million	Skr-84.11 Million ≈ $-9.05 Million	-0.182x	+6.91%
2017-12-31	Skr236.80 Million ≈ $25.48 Million	Skr-46.32 Million ≈ $-4.98 Million	-0.196x	-355.98%
2016-12-31	Skr276.63 Million ≈ $29.77 Million	Skr-11.87 Million ≈ $-1.28 Million	-0.043x	-26.43%
2015-12-31	Skr83.80 Million ≈ $9.02 Million	Skr-2.84 Million ≈ $-305.99K	-0.034x	+85.37%
2014-12-31	Skr35.74 Million ≈ $3.85 Million	Skr-8.29 Million ≈ $-892.20K	-0.232x	-176.53%
2013-12-31	Skr4.94 Million ≈ $531.55K	Skr-414.31K ≈ $-44.59K	-0.084x	--

About Immunovia publ AB

ST:IMMNOV Sweden Diagnostics & Research

Market Cap

$10.74 Million

Skr99.82 Million SEK

Market Cap Rank

#26966 Global

#581 in Sweden

Share Price

Skr0.15

Change (1 day)

-1.72%

52-Week Range

Skr0.13 - Skr0.52

All Time High

Skr290.00